Ivan Cherrez-Ojeda

and 36 more

Background: Information/communication technologies such as mobile phone applications (apps) would enable chronic urticaria (CU) patients to self-evaluate their disease activity and control. Yet, recently Antó et al (2021) reported a global paucity of such apps for patients with CU. In this analysis, we assessed patient interest in using apps to monitor CU disease activity and control using questions from the CURICT study, Methods: The methodology for CURICT has been reported. Briefly, a 23-item questionnaire was completed by 1,841 CU patients from 17 UCAREs across 17 countries. Here, we analyzed patient responses to the CURICT questions on the use of apps for urticaria-related purposes. Results: As previously published, the majority of respondents had chronic spontaneous urticaria (CSU; 63%; 18% chronic inducible urticaria [CIndu]; 19% with both), were female (70%) and in urban areas (75%). Over half of patients were very/extremely interested in an app to monitor disease activity (51%) and control (53%), while only ~1/10 were not. Patients with both urticaria types vs those with CSU only (OR, 1.36 [1.03-1.79]) and females vs males (OR[95%CI], 1.47 [1.17-1.85]) were more likely to be very to extremely interested in an app to assess disease control. Conclusions: Overall, patients with CU were highly interested in using an app to assess their disease activity and control. Development of well-designed apps, specific to disease types (CSU, CIndU, CSU+CIndU, etc), validated by experts across platforms would help improve the management and possibly outcomes of CU treatment while providing important patient information to be used in future research.

Jiahui Zhao

and 7 more

Background: Atopic dermatitis (AD) is one of the most prevalent chronic inflammatory skin disorders that causes great disease burdens world-wide. The demographics and clinical characteristics of AD are different between countries, regions, and age groups yet these differences were not well characterized in China. To get well guidance for AD clinicians, we described the demographics, clinical characteristics, comorbidities, patient-identified aggravating factors and treatment of AD in all-age patients in China. Methods: This study included Chinese individuals diagnosed with AD by accredited clinicians in the department of dermatology of 205 hospitals from 31/34 provincial administrative divisions across China during August, 2021 to September, 2022. All included patients completed dermatologist-lead interviews regarding their general medical history, comorbidities, AD-related aggravating factors and medications. Two-level mixed ordered logistic regression was used to evaluate factors for aggravation of the disease. Results: Overall, 16838 respondents were included in the final analysis with a mean age of 30.94 years (standard deviation, ± 24.08 years). The proportion of patients with severe AD was the highest in patients with onset of AD at ≥60 years old (26.73%). Allergic rhinitis and hypertension were the most common atopic and non-atopic comorbidities, respectively. AD severity was significantly associated with chronic urticaria, food allergy and diabetes. There was a high proportion of severe AD in patients who had aggravating factors such as seafood, lamb and beef, chili peppers, alcohol, seasonal changes, and psychological factors. Cross-sectional survey revealed unmet needs of severe AD in treatment strategy, in lack of immunosuppressants’ and biological agents’ application. Conclusion: Treatment of comorbidities and control of aggravating factors significantly contribute to AD management. Improving systemic immunotherapy could reduce the incidence of severe AD.

Xiaoting Song

and 5 more